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photosensitivity. Afterwards, she developed 
erythematous rashes on her arms, abdomen and 
both legs, accompanied with skin tightening. She 
also had alopecia and weight loss.
Physical examination on admission at our 
institution revealed normal vital signs. There 
were heliotrope rashes on her palpebras, and 
Gottron’s papules as well as Gottron’s sign over 
the surface of her metacarpophalangeal joints and 
elbows. She had rashes on her neck (shawl sign, 
V-sign), sclerodactyly, and muscular atrophy of her 
upper extremities. Rodnan skin score was 19. On 
palpation, the skin on her abdomen, arms, hands, 
legs, and feet felt tight and taut. She had diffi culty 
raising her arms and step on ladders or stand up 
from sitting position. 
Figure 1 Heliotrophe on patient’s eyes
Figure 2 Sclerodactyly and Gottron’s papules on PIP 
and DIP surface 
Figure 3 V sign and shawl sign
The classifi cation of rheumatic diseases is still 
challenging due to several reasons. First, those 
diseases have several differential clinical features, 
which giving overlap symptoms. Second, the 
etiopathogenesis of those diseases remains elusive. 
Diagnosis of overlap syndrome is made when 
there are more than one well-defi ned connective 
tissue diseases in one patient, which may develop 
simultaneously or sequentially.1,2 The prevalence of 
overlap syndrome among autoimmune diseases is 
25%.2
The term sclerodermatomyositis or 
scleromyositisis is used to describe an overlap 
syndrome in patients with scleroderma and 
dermatomyositis/polymyositis (DM/PM).2,3,4 
Sclerodermatomyositis usually affects adults, 
and it is rarely found in children.4 The clinical 
features of this syndrome are myalgia or myositis, 
arthralgia, scleroderma-like skin changes, 
Raynaud’s phenomenon (RP),2,3 interstitial lung 
disease, calcinosis,3 mask-like facies, dysphagia 
or esophageal dysmotility,4 as well as the presence 
of specifi c antibody Pm/Scl.2 Skin manifestations 
as the part of dermatomyositis include periorbital 
erythema and Gottron’s papules.3
We report this case due to its very rare occurrence. 
According to medical records in the Department of 
Dermatology as well as Rheumatology at Hasan 
Sadikin Hospital, Bandung, this is the fi rst case 
recorded in the last 10 years.
CASE REPORT
An 18-year-old, single, Sundanese female, came to 
our institution with chief complaint of rashes on her 
arms, hands, legs, and abdomen. 
Since 2 years prior to this visit, she has had 
complaint of joint pain on both elbows, with rashes 
on the surface of her knees and elbows, as well as 
photosensitivity and oral ulcers. At that time, his 
physician considered systemic lupus erythematosus 
(SLE) as the cause of her symptoms. Laboratory test 
results were normal, except for leucopenia (white 
blood cell count of 4 × 103/mm3).  At that time, 
the patient also had negative antinuclear antibody 
(ANA) and anti–double-stranded DNA (anti-
dsDNA) tests. She was given nonsteroidal anti-
infl ammatory drugs (NSAIDs) and subsequently 
showed improvement.
One year prior to admission, she started to 
have diffi culty swallowing foods and liquids, also 
accompanied with rough skin on her face, rashes 
on her eyelids, face, chest and back, as well as 
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Figure 4 Rashes on the patient’s arms and body
Her laboratory results were normal except for mild increase 
of lactate dehydrogenase (LDH) (456 U/L) and creatine kinase 
(CK) (20 U/L) as well as positive ANA test with speckled 
pattern. Anti-RNP was negative, neither anti-Jo-1 and anti-
Scl-70. Skin biopsy of her femoral area revealed stratifi ed 
squamous epithelium with atrophy and mild keratinization, 
with liquefactive degeneration of the basal layer in the center 
of the specimen. In dermis, a number of capillary arteries 
showed wall-thickening and fi brinoid degeneration. Masson’s 
trichrome and van Gieson’s stain showed thickening of some 
of the collagen fi brils. Direct immunofl uorescence of skin 
biopsy specimen showed no immunoglobulin (IgG, IgA, IgM), 
complement component 3 (C3), or fi brinogen deposition. 
Electromyography (EMG) was also performed in this patient, 
but the result was within normal limit.
Figure 5 Histopathological specimen from patient’s skin, 
showing  liquefactive degeneration (arrow)
The patient was diagnosed sclerodermatomyositis and 
was given methylprednisolone 0.8 mg/kg body weight daily, 
methotrexate (MTX) started 7.5 mg weekly, folic acid 1 mg 
daily, urea and mometasone cream, as well as sunscreen cream. 
She was referred to the Department of Medical Rehabilitation 
and Department of Clinical Nutrition for further assistance 
with her condition. 
On the follow-up at day 18, the skin rashes had reduced 
but the weakness and skin tautness remain. On day 43, the 
patient began to be able to climb stairs and rise from sitting 
position without help, although she still had diffi culty to stand 
up from squatting position. The skin lesions also began to 
diminish, except for the skin tautness and Gottron’s papules. 
Methylprednisolone was thus tapered down. 
On day 57, CK was 32.1 U/L and LDH decreased to 434 
U/L. On day 80, her condition continued to improve, Rodnan 
skin score was 10, and the patient could stand up from 
squatting position. 
DISCUSSION
Dermatomyositis is an idiopathic infl ammatory myopathy 
characterized by proximal muscle weakness and skin 
eruption.5 When the skin lesions are absent, the disorder is 
termed polymyositis. Involvement of proximal muscles is 
the characteristic feature of this disease.6,7 There are several 
types of dermatomyositis known: classic, amyopathic, 
and hypomyopathic dermatomyositis. The term classic 
dermatomyositis is used when myositis is accompanied 
with proximal muscle weakness and characteristic skin 
lesions. In amyopathic dermatomyositis there are skin lesions 
consistent with dermatomyositis which have been present 
for at least 6 months, without proximal muscle weakness 
or serum muscle enzymes abnormality. In hypomyopathic 
dermatomyositis, there is subclinical myositis found in 
laboratory examination.7,8,9
Creatine kinase level is important in myositis cases,8,9,10 
because of its relative sensitivity and specifi city in assessing 
the extent of muscle fi ber damage.7,10 In 80-90% cases of 
myositis, CK level are usually elevated in initial measurement, 
but subsequently become normal due to the decrease in muscle 
mass or inhibition to CK activity.10
Measurement of other enzymes, such as aldolase, aspartate 
and alanine aminotransferase, and LDH can also help in 
making the diagnosis of myositis, particularly in patients with 
active disease and normal CK level.9,10 When measurement of 
these enzymes is performed, it is important to consider that 
conditions such as liver diseases may also elevate the level of 
these enzymes.10
Erythrocyte sedimentation rate (ESR) may be elevated; 
however, it is not usually associated with disease activity. 
Elevation of rheumatoid factor (RF) may be encountered in 20% 
cases of dermatomyositis.7 Electromyography is a sensitive, 
but not specifi c method in diagnosing dermatomyositis;11 as 
many as 10% of patients may have normal results.7
In 60% of cases, skin lesions and proximal muscle 
weakness may occur simultaneously. Skin lesions are often 
accompanied by itching or burning sensation, and it may be 
triggered by exposure to sunlight or ultraviolet light.7 The 
predominant skin lesions in dermatomyositis are symmetric, 
confl uent, purplish erythematous macules over the extensor 
surface of fi ngers, dorsal aspects of hand, arm, deltoid area, 
back, and neck (shawl sign), in a “V”-like distribution over the 
anterior neck and upper chest (V-sign), and middle part of the 
face, periorbital area, forehead, and scalp.6,11
Characteristic lesions are often found around the eyes, 
appearing as a pink, scaly patch with itching, swelling, 
and violaceous change (heliotrope rash), or bulla.6 Other 
reported skin lesions in dermatomyositis include urticaria, 
photosensitivity, erythema nodosum, erythema multiforme, 
keratosis follicularis, hypertrichosis, livedoreticularis, 
hyperhidrosis, psoriasiform eruption, pitting nail, and ulcer.12 
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Exfoliative dermatitis may also occur in dermatomyositis, 
but rare. Diffuse alopecia may occur  on scalp.9,12 
Hyperpigmentation may occur later in the course of the 
disease.8,12 Recurrent aphtous stomatitis was reported in one 
case of sclerodermatitis.13 Periungual telangiectasia that is 
related to cuticular dystrophy is a characteristic lesion.11 In 
patients with positive anti-synthetase antibody, there may be 
hyperkeratotic lesion, fi ssures, and linear hyperpigmentation 
on the palmar surface of the hand, which termed mechanic 
hands.9,12
In 20% cases, dermatomyositis is accompanied by 
other connective tissue diseases (overlap syndrome); 
thus, it is important to look for characteristic symptoms 
of other connective tissue diseases.7,11 Dermatomyositis 
commonly overlaps with scleroderma, and it is called 
sclerodermatomyositis.6
Early in the course of the disease, weakness occurs 
in muscles on shoulder and waist; therefore, the patients 
had diffi culty in performing specifi c movements such as 
moving arms upward, or stand up from sitting position. 
Muscle weakness may be accompanied by muscle pain and 
tenderness.7 Patients with dermatomyositis often complains 
malaise and fatigue. Myopathy affects proximal muscle 
groups, particularly triceps and quadriceps,11 with symmetrical 
distribution.6,11 Later in the course of the disease, all muscle 
groups may be affected.11 Other systemic disorders that  also 
occurred in dermatomyositis were calcinosis of deep fascia 
and muscles,11,12 disorder of the lung and heart, arthritis,11 
kidney, gastrointestinal system,7,11 eyes, and malignancy.7,12
In 1972, Sharp et al introduce the term “mixed connective 
tissue disease” (MCTD), a disorder characterized by 
combination of two or more autoimmune diseases: SLE, 
progressive systemic sclerosis (PSS), dermatomyositis, or 
polymyositis.14,15 The main symptoms of MCTD include 
Raynaud’s phenomenon (93% of cases), arthralgia/joint 
involvement (93%), edema of the fi ngers and hand (71%), 
lymphadenopathy (71%), myositis/muscle involvement 
(50%), serositis (29%), hepatomegaly (21%), and 
splenomegaly (21%). Other symptoms include esophageal 
refl ux, sclerodactyly, and lung involvement.14,16 Diagnosis 
of MCTD should be considered when there are clinical 
presentation of SLE, PSS, dermatomyositis, or polymyositis 
in one patient.16,17 Characteristic serological fi ndings are high 
ANA titer (usually more than 1:1000) with speckled pattern, 
anti-RNP, and anti-U1RNP antibodies.14,15 Antibodies such as 
anti-dsDNA, anti-SSa, anti-SSb, or anti-Smith are not usually 
found in MCTD. Although our patient had high titer of ANA, 
the diagnosis of MCTD can be excluded since the anti-RNP 
antibody was negative.
Scleroderma or systemic sclerosis (SSc) is a chronic 
multisystem disorder, characterized by sclerosis of connective 
tissue,18,19 vascular disorder, and involvement of visceral 
organs.12 The diagnostic criteria for SSc have been made by 
the Subcomittee for Scleroderma Criteria of the American 
Rheumatism Association and have been widely used, in 
which, for the diagnosis to be made, the patient must have 
(1) proximal scleroderma on the fi ngers, extremities, face, 
neck or the trunk; or (2) at least 2 of the minor criteria: (a) 
sclerodactyly, (b) digital pitted scarring, (c) bilateral basal 
pulmonary fi brosis.12 These criteria have a sensitivity and 
specifi city of 97% and 98%, respectively.46,12
Systemic sclerosis is classifi ed into localized cutaneous 
SSc (lcSSc) and diffuse cutaneous SSc (dcSSc). The difference 
between the two type lies in the extent of skin involvement 
and other clinical and immunological presentations.6,12
Clinical manifestations in lcSSc are marked by history of 
Raynaud’s phenomenon (in 1 to 10 years) before tightening 
of the skin on the distal extremities, without involvement 
of the trunk. In lcSSc, the classic CREST syndrome may 
also be found: calcinosis cutis, Raynaud’s phenomenon, 
esophageal dysfunction, sclerodactyly, and telangiectasia.18,20 
Visceral organ involvement include pulmonary hypertension, 
pulmonary fi brosis, and gastrointestinal system. Vascular 
involvement include ischemia and ulceration of the fi ngers, 
and gangrene that may result in autoamputation.18,19
The patient in this case report was diagnosed with 
sclerodermatomyositis based on history of pain in both elbows, 
with diffi culty in raising the arms and standing up from sitting 
position. Those complaints were also accompanied by skin 
changes on face, elbows, hands, abdomen, knees, and legs, 
which were characteristics of dermatomyositis. There were 
also history of dysphagia, diffi culty opening the mouth, 
Raynaud’s phenomenon, and tight and hard skin on arms and 
legs, which support the diagnosis of scleroderma.
On physical examination, we found skin lesions that 
support the diagnosis of dermatomyositis: heliotrope rash, 
Gottron’s papules, and shawl sign. Those skin lesions were 
also accompanied by muscle atrophy, alopecia, as well as pain 
and stiffness of the proximal muscles. Physical examination 
that support the diagnosis of scleroderma were Raynaud’s 
phenomenon, sclerodactyly, and skin hardening of the arms, 
hands, fi ngers, abdomen, and legs. The level of LDH in the 
patient was increased, with normal level of other muscle 
enzymes.
The erythematous lesion and edema in dermatomyositis 
commonly exhibit nonspecifi c histopathological appearance.12,21 
The histopathological fi ndings in dermatomyositis include 
epidermal atrophy, basement membrane degeneration, 
vacuolar changes of basal keratinocytes, and dermal changes, 
such as interstitial mucin deposits with rare lymphocyte 
infi ltration.6,11,21
The epidermis in SSc may appear normal, atrophic, or 
thickened. The dermis may appear thicker and consist of 
dense collagen bundles that can be visualized by trichrome 
staining.22
The histopathological examination of the patient’s 
skin revealed atrophy, mild keratinization, liquefactive 
degeneration of the basal layer in the center, and thickening 
of the basement membrane. This appearance could also be 
found in dermatomyositis. Trichrome staining did not show 
thickening of collagen.
Positive ANA may be found in 50-80% of dermatomyositis 
cases, particularly in patients with overlap syndrome.6,10 
Common ANA patterns were speckled and nucleolar pattern.7 
Autoantibodies in patients with dermatomyositis are divided 
into 2 groups: myositis-specifi c and myositis-associated 
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antibodies. The fi rst group is found in <50% of patients and 
has a worse prognosis. Antibodies such as anti–histidyl-
tRNA synthetase (anti–Jo-1) belong to this group. The 
second group is found in 30-40% of patients, which include 
anti-Ro/SSA and anti-U1RNP. Anti-PM/Scl, anti-Ku, and 
anti-U2RNP antibodies are found in patients with overlap 
of dermatomyositis and scleroderma.7 Anti-PM/Scl is found 
in 24% of dermatomyositis cases, but it could also be found 
in 8% of polymyositis cases and 3% of scleroderma cases.15 
Positive anti-PM/Scl antibodies is often associated with 
nucleolar pattern of ANA.4
More than 90% of patients with scleroderma have positive 
ANA.23 Positive ANA with nucleolar pattern is specifi c for 
scleroderma; however, speckled pattern can also be found, as 
well as in patients with CREST syndrome,6 dermatomyositis, 
or MCTD. Scl-70 autoantigen may be found in 70% of dcSSc. 
Anticentromere antibodies may be found in 50-96% of lcSSc 
patients.24
The patient had positive ANA with speckled pattern; 
however, ANA profi le did not show signifi cant increase in the 
level of autoantibodies.
There is a marked difference in terms of response to therapy 
between muscle and skin involvement.5,11 Skin manifestations 
in dermatomyositis are usually more diffi cult to treat. The 
American Academy of Dermatology (AAD) recommend 
aggressive protection against sunlight with physical barrier, 
sunscreen, and topical corticosteroid.1,5 Because patients with 
dermatomyositis usually have xerosis, the use of moisturizers 
will also be benefi cial. Topical antipruritics may also given 
relieve to itchy skin lesions.7,8,25 Patients are advised to use 
sunscreen with high SPF (>30) daily, avoid direct exposure 
to sunlight, cold temperatures, stress, and perform regular 
exercise to maintain joint mobility.5
Systemic corticosteroid is the therapy of choice in 
dermatomyositis, given as daily-dose prednisone or pulse-dose 
methylprednisolone.24,25,26 The AAD recommends systemic 
corticosteroid for early control of muscle disease with a dose 
of 0.5-1.5 mg/kg/day. After control of the disease is achieved, 
the dose could be tapered down, usually every 4 to 6 weeks.5,6 
As many as 50-75% of dermatomyositis cases that are given 
corticosteroid showed complete remission.25
Other immunosuppressant drugs such as MTX, 
azathioprine, cyclophosphamide, cyclosporine,6,25,26 and 
mycophenolate mofetil26 can be given to control the disease 
and accelerate the tapering of corticosteroid.25 A study that 
compared MTX and azathioprine showed no difference in 
effi cacy between the two drugs, although the side effects of 
MTX was more tolerable.26
For dermatomyositis, MTX may be given early in the 
course of the disease or for refractory cases.5,9 It may also be 
given to patients with SSc.18,27 MTX is given when there is 
inadequate response to prednisone,5 but it may also be given 
in combination with prednisone as fi rst-line therapy in severe 
myositis.26 Weekly dose of MTX is usually 7.5-25 mg orally.7 
Approximately 70-77% of patients who need adjuvant therapy 
showed response to MTX therapy.5 Before starting initial 
therapy of MTX, thorough examination of the patient should 
be conducted, including routine laboratory examination 
that comprise of complete blood count and liver and kidney 
function test.27 MTX may reduce diffuse skin hardening in 
scleroderma, but further studies are needed to confi rm this.6
Bed rest is advised to patients with dermatomyositis who 
have severe infl ammation; however, exercise and physical 
therapy are also needed as part of rehabilitation and therapy 
of dermatomyositis. In the evaluation, clinician should make 
a decision concerning the need of exercise program in each 
patient. The program should be arranged by physiotherapist, 
starting from passive and continued to active exercise. After 
the improvement of clinical condition, passive therapy can be 
continued with active therapy.5,25
Our patient was advised to avoid exposure to cold and 
sunlight. Topical therapies given were moisturizer, sunscreen, 
and topical corticosteroid. Systemic therapies were systemic 
corticoisteroid given in 0.8 mg/kg prednisone-equivalent dose 
and MTX with a dose of 7.5 to 10 mg per week.
The mortality rate of dermatomyositis ranges between 
8.9 to 52 percent, depending on the variation of the clinical 
presentation.5 Mortality in dermatomyositis is mainly caused 
by malignancy,6 ischemic heart disease, and lung disease.6,7,12 
Sclerodermatomyositis usually has better prognosis.4,7 In the 
last two decaces, the mortality rate of dermatomyositis has 
been declining, owing to the use of corticosteroid and other 
immunosuppressant drugs;7 however, the risk of malignant 
degeneration is still high, particularly in the fi rst 5 years 
since diagnosis.28 Most patients showed good response to 
therapy, but in some cases there may be residual muscle pain12 
or muscle weakness29 despite the inactivity of the disease. 
Relapse may occur at any time, including when the steroid 
dose is being tapered.25,29
SUMMARY
We have reported a rare case of sclerodermatomyositis, an 
overlap syndrome between scleroderma and dermatomyositis. 
Characteristic feature of the disease that were found in the 
patient include typical skin changes, sclerodactyly, arthralgia, 
muscle weakness, and positive ANA with speckled pattern. 
After establishing the diagnosis, the patient was given emollient 
and  sunblock for topical  treatment, oral corticosteroid, 
and methotrexate  systemic treatment.  Signifi cant clinical 
improvement was  observed during her follow-ups.
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